FIG. 4.
Protective efficacy of EbolaΔVP30 virus in mice. Mice (n = 15) were immunized twice with EbolaΔVP30 virus; nonvaccinated mice (n = 10) were inoculated with PBS. Eight weeks after the second vaccination, mice from the vaccinated and nonvaccinated groups were challenged with 1,000 MLD50 of MA-EBOV. A control group (Mock, n = 3) remained nonvaccinated and nonchallenged. Survival curves are shown.